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Human immunodeficiency virus type 1 (HIV-1) can infect CD4+ lymphocytes, monocytes-macrophages, and
various other cell lines, including B-cell lines. To study the parameters of B-cell infections, we examined the
susceptibility of 24 B-lymphoid cell lines to both HIV-1 and HIV-2 infections. These cell lines included a series
of Epstein-Barr virus (EBV) genome-negative Burkitt's lymphoma cell lines and their EBV-converted
counterparts. To infect these cells we used two HIV-1 isolates and one HIV-2 isolate. Infections were monitored
with a cytoplasmic RNA dot-blot and a syncytium assay. HIV infection was also studied by a novel method
based on electrophoresis of DNA liberated from cells that were lysed in situ in the well of an agarose gel. All
human B-cell lines could be infected with HIV-1, regardless of the presence of EBV genomes; thus, EBV
infection had no major effect on HIV susceptibility of B-cell lines. Integrated proviral HIV genomes could be
detected by Southern blot analysis of DNA extracted from long-term, non-HIV-producing B-cell lines. This
study suggests that B-lymphoid cells may serve as reservoirs for latent or persistent HIV infections in vivo, even
in the absence of EBV infection.
While the human immunodeficiency viruses (HIV) prefer-
entially infect and often deplete T4 lymphocytes (3, 7), a
major unanswered question is why the latency period for the
onset of acquired immunodeficiency syndrome (AIDS) can
vary from a few months to more than 7 years. One explana-
tion could be the ability of other viruses to act as cofactors
in the stimulation of HIV expression and subsequent deple-
tion of the T4 lymphocytes. It has been shown that HIV type
1 (HIV-1) can productively infect Epstein-Barr virus-posi-
tive (EBV+) lymphoblastoid cells (5, 12, 15, 18, 22). HIV-1
infection of EBV+ B cells can result either in a persistently
infected culture or in complete cytolysis of the culture,
depending on the cell line and virus dilution (5). Several
DNA viruses, including herpesviruses (cytomegalovirus,
HSV-1, and EBV), can stimulate expression of HIV-1 by
transactivation of the HIV-1 long terminal repeat (9, 10, 16).
This study was designed to examine the susceptibility of
various B-lymphoid cell lines to HIV infection ahd to inves-
tigate the effect of prior EBV infection on the infectivity of
these B cells by HIV. Most cell lines established from
African and AIDS-associated Burkitt's lymphomas (BLs)
are EBV+, whereas the majority of European and American
non-AIDS-associated BLs are EBV-. Recently, one of us
(A.C.) established a series of such EBV- cell lines from
non-AIDS-associated European BL (4) and infected some of
these cells with either the nonimmortalizing EBV strain
P3HR-1 or the immortalizing EBV strain B95-8 to be able to
study, in parallel, EBV- BL cells and their EB3V-converted
counterparts prior to extensive tissue culture passage. These
cell lines (BL30, BL31, BL40, BL41, and BL70), another
EBV- BL cell line (CA-46), an older series of EBV- and
EBV-converted BL cells (RAMOS), and seven existing
EBV+ B-lymphoid cells of various origin (Table 1) were
infected with HIV-1 and HIV-2. CEM, a human T4 leukemia
cell line, was included as a positive for productive infection.
B95-8, an EBV+ lymphoblastoid cottontopped marmoset
* Corresponding author.
B-cell line, was also infected with HIV-1 and HIV-2, since
its progeny virus was used to convert several of the EBV-
BL cells. It was observed that all human EBV- as well as
EBV+ cell lines could be infected with HIV.
The B-lymphoid cell lines used in this study are listed in
Table 1, with their current EBV status. Cells were tested for
the presence of EBV nuclear antigens by anticomplement
immunofluorescence staining (17). EBV genomes were de-
tected with Gardella gels (8), a simple gel electrophoretic
technique utilizing intact cells. In addition, all EBV- cell
lines were examined by Southern blot analysis (21) to
confirm the absence of EBV genomes. These cell lines were
also tested for the expression of CD4 antigen by indirect
immunofluorescence using monoclonal antibodies OKT4a,
Leu-3a, and MT151; CD4 is the HIV-1 and HIV-2 receptor
(6, 11, 19a, 20).
Two types of HIV-1 were used to examine differences
between various isolates. HTLV-IIIB (HIV-1 IIIB) is cyto-
pathic for T4 lymphocytes, and HTLV-IIIRF (HIV-1 RF) is
more highly cytopathic. In addition, we used one strain of
HIV-2 (LAV-2 ROD, 1-532) to study group-specific differ-
ences on B-cell infection. No data have previously been
reported on HIV-2 infection of B-lymphoid cells. Each
infection was repeated a minimum of three times.
In all, 3 ml of cells (at 106/ml) was infected with 0.1 ml of
virus stock (stored at -70°C) and incubated at 37°C in 5%
CO2 for 24 h. An equal volume of fresh medium (RPMI 1640-
10% fetal calf serum) was added on day 2. BL cell lines were
fed with RPMI 1640-20% FCS. Cells were sampled and fed
with the same medium twice weekly, starting on day 4. HIV
infection was monitored by using the cytoplasmic RNA
dot-blot assay for HIV-1 (14) along with the C-8166 syncy-
tium assay for HIV-1 and HIV-2. The syncytium assay (23)
was performed by mixing equal volumes (0.5 ml) of C-8166
indicator cells (19) (5 x 105 cells) and cell-free supernatant
from the infected cultures in 24-well tissue culture plates.
The cultures were monitored for syncytium formation at 24,
48, and 72 h. For each virus stock used, titers were deter-
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TABLE 1. HIV infection of 24 EBV+ and EBV- B-cell linesa
Cellline Origin" EI3NA~~C EBV CD4 HIV infectivitydCell line ' BNA' genome antigen IIIB DB IIIB SYN RF DB RF SYN HIV-2 SYN
Jijoye AfrBL + + - ++ ++ +++ +++ +/-
P3HR-1 Jijoye + + - +1- + + + +
Raji Afr BL + + - - + + +++
8392 LCL + + - ++ +++ +++ +++ ++
IB4/B95-8 LCL + + ND +++ +++ +++ +++ -
QIMR-WIL LCL + + ND - + + ++ -
CA-46 BL - - ND ++ +++ ++ +++ ++
BL30 Eur BL - - - - + +/- ++
BL30E1/P3HR-1 BL30 + + ++ +++ +++ +++ +++ ++
BL30E2/P3HR-1 BL30 + + - + ++ +++ +++ +++
BL31 Eur BL - - - + ++ ++ +++
BL31E/B95-8 BL31 + + + +++ +++ +++ +++ +++
BL40 Eur BL - - - - + - + + +
BL40E/B95-8 BL40 + + + +/- + + +++ + +
BL41 Eur BL - - + - + + +++ +
BL41E/B95-8 BL41 + + ++ +++ +++ +++ +++ +++
BL70E1/P3HR-1 BL70 (Eur BL) + + - - + +- + + + +
BL7OE2/P3HR-1 BL70 + + + + ++ ++
BL7OE3/B95-8 BL70 + + ++ +++ +++ +++ +++ +++
RAMOS Amer BL - - +- ++ ++ ++ +++ +
RAMOS2/P3HR-1 RAMOS + + + +++ +++ +++ +++ + +
RAMOS3/P3HR-1 RAMOS + + - + ++ + + +++ + +
RAMOS4/P3HR-1 RAMOS + + + +++ +++ +++ +++ + +
RAMOS5/B95-8 RAMOS + + +- + +++ +++ +++ ++
B95-8 CTM-LCL + + - - - - - -
CEM TCL - - ++ +++ +++ +++ +++ +++
a Cell lines were tested for EBV nuclear antigens, EBV genomes, and CD4 antigen as described in the text. HIV infection with similar titers was also performed
as described in text.
I LCL, Lymphoblastoid cell line; CTM-LCL, cottontopped marmoset lymphoblastoid cell line; TCL, T-cell leukemia; Afr BL, African Burkitt's lymphoma;
Eur BL, European Burkitt's lymphoma; Amer BL, North American Burkitt's lymphoma.
c EBNA, EBV nuclear antigen.
d IIIB, HIV-1 IIIB; RF, HIV-1 RF; DB, Dot-blot assay; SYN, C-8166 syncytium assay; ND, not done; -, never observed; +/-, occasionally observed; +,
weak; + +, strong; + + +, very strong.
mined on C-8166 cells and appropriate dilutions were made
so that each virus inoculum had a similar titer.
The results of both the cytoplasmic RNA dot-blot and the
C-8166 syncytium assays are listed in Table 1. Since HIV-2
has very low genomic homology to HIV-1 and since HIV-2
clones were not yet available to us for hybridization, only
the syncytium assay was used to detect HIV-2 infection.
All 24 human B-cell lines tested could support HIV
production of at least the two HIV-1 isolates used; 19 of
these could also be productively infected with HIV-2. HIV-1
RF consistently gave the highest yield of HIV-1 RNA and
the strongest syncytium production in the majority of the cell
lines studied. About half of the EBV+ cell lines showed high
HIV production (Table 1). High levels of both cytoplasmic
RNA and extracellular virus could be detected in these cells
well past 30 days after infection. No production of HIV
could ever be detected in the cottontopped marmoset B95-8
cell line, although cottontopped marmoset T4 lymphocytes
are infectible by HIV-1 and HIV-2 (13; our unpublished
results).
All of the six EBV- Burkitt's lymphoma cell lines exam-
ined could be productively infected with HIV-1. Earlier
reports (14, 17) that EBV- B cells could not be productively
infected with HIV-1 are clearly at odds with our results.
Those results could be due to the use of a less virulent virus
strain, lower virus titers, less sensitive assays used by
Salahuddin et al., or a combination of these three phenom-
ena (18). Thus, this is the first report of an EBV- B-cell line
productively infected by HIV. Production of HIV-1 IIIB in
three of the six EBV- cell lines (BL30, BL40, and BL41)
was very weak and was detectable only with the syncytium
assay. This was also the situation with some of the EBV+
cell lines for HIV-1 IIIB infection.
To confirm that these cell lines with very low virus
production were truly infected with HIV-1, cell-free super-
natants from cultures at 10 days postinfection were used to
infect CEM cells. These CEM cells were then tested for
HIV-1 production by the dot-blot assay, starting on day 7
postinfection. Most of the HIV-1 infections that had been
either negative or weakly positive with the dot-blot assay
(Table 1) were tested in this manner. Of the 10 such
infections examined, only 1 remained negative by dot-blot
assay after CEM infection (data not shown): the HIV-1 IIIB
infection of the BL-40 cell line. Since the B95-8 cell line was
always negative for HIV infection, supernatants from B95-8
cultures were included in the CEM infections as a negative
control to ensure the absence of residual virus from the
original inoculum. CEM cells infected with the supernatants
of the HIV-infected B95-8 cells remained negative.
While HIV production could be detected in the EBV-
cells (Table 2), we observed that, unlike infection of the
EBV+ cells, HIV infection of several of the cell lines
resulted in cytolysis by day 12 after infection. This phenom-
enon occurred with the BL30, BL40, and BL41 cell lines and
occasionally with the BL31 cell line. Most of the uninfected
EBV- BL cell lines were very fastidious when compared
with their EBV-converted counterparts. This could explain
the different types of biological behavior after HIV infection.
However, HIV infection of the CA-46 and RAMOS EBV-
cell lines always yielded a persistent infection similar to that
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TABLE 2. HIV infection of EBV- B-cell linesa
HIV PersistentlyCell line infectivityb Cytolysisc infectedinfectivity
~~~~~~~cells'
BL30 + + -
BL31 + + +I- +I-
BL40 +/- + -
BL41 + + -
CA-46 +++ - +
RAMOS +++ - +
a
-, Never observed; +/-, occasionally observed; +, weak; + +, strong;
+ + +, very strong.
b HIV infectivity of each cell line was scored by compiling the data in
Table 1.
c Cell destruction occurring between days 10 and 14 postinfection.
d Cell cultures that survived past 30 days postinfection.
of the HIV-infected EBV+ cell lines. BL31 infections usu-
ally resulted in persistent HIV infections, but with lower
HIV yields.
A majority of cell lines were tested for the expression of
CD4 antigen by indirect immunofluorescence with three
monoclonal antibodies against CD4. These results are listed
in Table 1. Several HIV-infectible cell lines expressed no
detectable CD4 surface markers. Similar results had been
reported earlier (18). Although these results could be inter-
preted to indicate the existence of alternative HIV receptors
besides CD4 (18), other possible explanations appear more
attractive. Several nonlymphoma cell lines without detect-
able CD4 surface expression, but infectible by HIV-1, were
subsequently found to contain CD4 mRNA (2; J. Weber,
personal communication). Similarly, HIV-1 infection of Raji
cells could be blocked by MT151, an anti-CD4 monoclonal
antibody (C.M. and P. R. Clapham, unpublished observa-
tion). Both of these observations indicate CD4 expressions,
albeit at a low level, and the use ofCD4 as the HIV receptor.
Therefore, we are currently testing several of the B-cell lines
for the presence of CD4 mRNA and for the ability to block
infection with antibodies against CD4 epitopes.
DNA extracted from several long-term-HIV-infected cell
lines (BL31E, RAMOS 2, Jijoye, P3HR-1, and CEM) were
positive for HIV genomes by Southern blot analysis (data
not shown). At the time of extraction, these cells were
producing only very low levels of or no detectable HIV-1
RNA as measured by the dot-blot assay. This finding sug-
gests that these cells had been latently infected with HIV.
To monitor HIV-1 genome production in the initial stages
of infection, we subjected infected B cells to a modified
Gardella gel analysis (8). A suspension of 106 B cells, at
various days postinfection, was pipetted into the wells of a
vertical agarose gel (1.4%) and overlaid with sodium dodecyl
sulfate and pronase. Electrophoresis of sodium dodecyl
sulfate into the cell layer, at low voltage, induces a very
gentle lysis of the cell and nucleus. As a result, the cellular
DNA remains too large to enter the gel, and only small DNA
such as unintegrated proviral DNA enters the gel and can
then be detected by hybridization as two or three bands, a
covalently closed circular DNA, and a linear DNA that
migrates below a diffuse band of broken cellular DNA (100 to
500 kilobases); this diffuse band is probably derived from
dead cells (8). The hybridization frequently detected at the
top of the gel could be due to integrated proviral DNA or
unintegrated proviral DNA, or both, trapped in the network
of high-molecular-weight cellular DNA. This simple gel
technique requires only a small number of cells (5 x 105 to 1
x 106) and does not require DNA extraction and purifica-
o 4 8 11 15 18 21 days CP. i.
FIG. 1 Detection of circular and linear HIV-1 DNAs in an
HIV-1 RF-infected EBV' lymphoid cell line (BL41E). A suspension
of 106 cells from an HIV-1 RF-infected culture was sampled on days
0, 4, 8, 11, 15, 18, and 21 postinfection (p.i.) as described in the text.
The control lane (C) contains both the circular (c) and linearized (1)
forms of pH6B5.0, a 10-kilobase plasmid with pBR322 sequences
which cross-hybridize to pJM(HIV-1)8.9, the HIV-1 clone (12) used
for hybridization. The band between the origin of the gel and the
circular band in the control lane represents a small portion of nicked
circular DNA that was present in the original plasmid preparation.
tion. A higher-percentage agarose gel (1.4%) instead of the
normal 0.75% gel used for larger episomal DNA (8) was used
for this study to achieve better separation of the circular and
linear forms of the HIV genome. In the 0.75% gel, the
circular and linear forms of 10-kilobase plasmid migrate very
close together, whereas in a 1.4% gel the linear form
migrates much faster than the circular band. The relative
position of each band was detected by running each form in
separate lanes (data not shown). The relative positions of
linear and covalently closed circular molecules depend on
size and agarose concentration (1).
Using this method, we consistently detected high levels of
both circular and linear unintegrated HIV-1 genomes 8 days
postinfection (Fig. 1). The number of unintegrated genomes
diminished thereafter and, by day 21 postinfection, became
barely detectable (Fig. 1). The double band visible at the
circular region of the HIV-1 RF-infected cells could possibly
represent a mixture of circular genomes with one and two
copies of the long terminal repeat region.
While most EBV' B cells produced higher amounts of
HIV and HIV RNA than their EBV- counterparts, it was
clearly seen that they can all be productively infected with
HIV. It was also observed that one isolate of HIV (HIV-1
RF) is more virulent for these B cells than other isolates
(HIV-1 TuIB, and HIV-2 ROD). This study indicates that
most B-lymphoid cell lines (both EBV- and EBV') can be
persistently infected with HIV. Therefore, we have to con-
sider the hypothesis that in vivo B cells serve as reservoirs
for HIV infection. These results should also act as a warning
against the use of spontaneous or EBV-induced B-cell lines
established from individuals with unknown HIV status.
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